Genetics of Resistant Hypertension: the Missing Heritability and Opportunities

• Published in: Current hypertension reports Vol. 20; no. 6; pp. 48 - 6
• Main Authors: Teixeira, Samantha K., Pereira, Alexandre C., Krieger, Jose E.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2018; Springer Nature B.V
• Subjects: Blood pressure; Blood Pressure - physiology; Cardiology; Family Medicine; General Practice; Genetic Predisposition to Disease; Genetic Testing; Genome-Wide Association Study - methods; Genomes; Humans; Hypertension; Hypertension - diagnosis; Hypertension - genetics; Hypertension - physiopathology; Internal Medicine; Medicine; Medicine & Public Health; Metabolic Diseases; Nephrology; Phenotype; Primary Care Medicine; Resistant Hypertension (L Drager; Section Editor; Topical Collection on Resistant Hypertension; Forward genetic screens, mutagenesis; Genetics; GWAS; Resistant hypertension
• ISSN: 1522-6417; 1534-3111
• DOI: 10.1007/s11906-018-0852-4

Purpose of the Review Blood pressure regulation in humans has long been known to be a genetically determined trait. The identification of causal genetic modulators for this trait has been unfulfilling at the least. Despite the recent advances of genome-wide genetic studies, loci associated with hypertension or blood pressure still explain a very low percentage of the overall variation of blood pressure in the general population. This has precluded the translation of discoveries in the genetics of human hypertension to clinical use. Here, we propose the combined use of resistant hypertension as a trait for mapping genetic determinants in humans and the integration of new large-scale technologies to approach in model systems the multidimensional nature of the problem. Recent Findings New large-scale efforts in the genetic and genomic arenas are paving the way for an increased and granular understanding of genetic determinants of hypertension. New technologies for whole genome sequence and large-scale forward genetic screens can help prioritize gene and gene-pathways for downstream characterization and large-scale population studies, and guided pharmacological design can be used to drive discoveries to the translational application through better risk stratification and new therapeutic approaches. Summary Although significant challenges remain in the mapping and identification of genetic determinants of hypertension, new large-scale technological approaches have been proposed to surpass some of the shortcomings that have limited progress in the area for the last three decades. The incorporation of these technologies to hypertension research may significantly help in the understanding of inter-individual blood pressure variation and the deployment of new phenotyping and treatment approaches for the condition.